News
Why Regions Financial (RF) is a Top Value Stock for the Long-Term
Taking full advantage of the stock market and investing with confidence are common goals for new and old investors, and Zacks Premium offers many different ways to do both.
The popular research
Should Value Investors Buy Genesco (GCO) Stock?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the
Are Investors Undervaluing Orix Corp Ads (IX) Right Now?
Here at Zacks, we focus on our proven ranking system, which places an emphasis on earnings estimates and estimate revisions, to find winning stocks. But we also understand that investors develop
Are Investors Undervaluing REMAX (RMAX) Right Now?
While the proven Zacks Rank places an emphasis on earnings estimates and estimate revisions to find strong stocks, we also know that investors tend to develop their own individual strategies. With
FirstEnergy (FE) is a Top-Ranked Value Stock: Should You Buy?
For new and old investors, taking full advantage of the stock market and investing with confidence are common goals. Zacks Premium provides lots of different ways to do both.
The research service
Is Carter's (CRI) Stock Outpacing Its Consumer Discretionary Peers This Year?
The Consumer Discretionary group has plenty of great stocks, but investors should always be looking for companies that are outperforming their peers. Is Carter's (CRI) one of those stocks right now
Is Aldeyra Therapeutics (ALDX) Outperforming Other Medical Stocks This Year?
The Medical group has plenty of great stocks, but investors should always be looking for companies that are outperforming their peers. Has Aldeyra Therapeutics, Inc. (ALDX) been one of those stocks
Here's Why Copa Holdings (CPA) is a Strong Value Stock
Taking full advantage of the stock market and investing with confidence are common goals for new and old investors, and Zacks Premium offers many different ways to do both.
The popular research
Should Value Investors Buy CNO Financial Group (CNO) Stock?
The proven Zacks Rank system focuses on earnings estimates and estimate revisions to find winning stocks. Nevertheless, we know that our readers all have their own perspectives, so we are always
Why EQT Corporation (EQT) is a Top Value Stock for the Long-Term
For new and old investors, taking full advantage of the stock market and investing with confidence are common goals. Zacks Premium provides lots of different ways to do both.
Featuring daily updates
Is Mama's Creations, Inc. (MAMA) Outperforming Other Consumer Staples Stocks This Year?
For those looking to find strong Consumer Staples stocks, it is prudent to search for companies in the group that are outperforming their peers. Has Mama's Creations, Inc. (MAMA) been one of those
Are Investors Undervaluing Mazda Motor (MZDAY) Right Now?
Here at Zacks, we focus on our proven ranking system, which places an emphasis on earnings estimates and estimate revisions, to find winning stocks. But we also understand that investors develop
Is Movado Group (MOV) Stock Outpacing Its Retail-Wholesale Peers This Year?
Investors interested in Retail-Wholesale stocks should always be looking to find the best-performing companies in the group. Is Movado (MOV) one of those stocks right now? Let's take a closer look
Here's Why Anheuser-Busch Inbev (BUD) is a Strong Value Stock
Taking full advantage of the stock market and investing with confidence are common goals for new and old investors, and Zacks Premium offers many different ways to do both.
The popular research
RVMD Reports Wider-Than-Expected Q4 Loss, Issues 2026 Expense View
Revolution Medicines RVMD reported a fourth-quarter 2025 loss of $1.86 per share, wider than the Zacks Consensus Estimate of a loss of $1.56. The company had incurred a loss of $1.12 in the year-ago
Zacks Market Edge Highlights: Union Pacific, CH Robinson Worldwide, Nutrien, Lear and Exxon Mobil
For Immediate Release
Chicago, IL – February 26, 2026 – Zacks Market Edge is a podcast hosted weekly by Zacks Stock Strategist Tracey Ryniec. Every week, Tracey will be joined by guests to discuss
Weave Communications (WEAV) Loses 26% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
Weave Communications, Inc. (WEAV) has been on a downward spiral lately with significant selling pressure. After declining 26.1% over the past four weeks, the stock looks well positioned for a trend
Gossamer Bio (GOSS) Loses 85% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
A downtrend has been apparent in Gossamer Bio (GOSS) lately with too much selling pressure. The stock has declined 85.1% over the past four weeks. However, given the fact that it is now in oversold
Down 26.2% in 4 Weeks, Here's Why Paylocity (PCTY) Looks Ripe for a Turnaround
A downtrend has been apparent in Paylocity (PCTY) lately with too much selling pressure. The stock has declined 26.2% over the past four weeks. However, given the fact that it is now in oversold
Is the Options Market Predicting a Spike in Amtech Systems Stock?
Investors in Amtech Systems, Inc. ASYS need to pay close attention to the stock based on moves in the options market lately. That is because the Mar 20, 2026 $22.50 Call had some of the highest
Implied Volatility Surging for Banco de Chile Stock Options
Investors in Banco de Chile BCH need to pay close attention to the stock based on moves in the options market lately. That is because the April 17, 2026 $30.00 Call had some of the highest implied
Compared to Estimates, Nvidia (NVDA) Q4 Earnings: A Look at Key Metrics
Nvidia (NVDA) reported $68.13 billion in revenue for the quarter ended January 2026, representing a year-over-year increase of 73.2%. EPS of $1.62 for the same period compares to $0.89 a year ago.
Donaldson (DCI) Reports Q2 Earnings: What Key Metrics Have to Say
For the quarter ended January 2026, Donaldson (DCI) reported revenue of $896.3 million, up 3% over the same period last year. EPS came in at $0.83, compared to $0.83 in the year-ago quarter.
The
Compared to Estimates, Sarepta Therapeutics (SRPT) Q4 Earnings: A Look at Key Metrics
Sarepta Therapeutics (SRPT) reported $442.93 million in revenue for the quarter ended December 2025, representing a year-over-year decline of 32.7%. EPS of -$3.58 for the same period compares to


